glp-1 microbiome Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy Bidirectional Interactions Between the Gut

A supplement cites a percentage increase in GLP-1 levels without clearly stating the data comes from mouse or rat studies

Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective

Company Market Share Analysis 2023 40 11.1.1

Inulin consumption not only promoted weight loss but was also associated with greater loss of triglyceride in the liver (IHCL) and soleus muscle (IMCL-S), even after controlling for differences in weight lost

The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results

It is typically more suitable for lighter skin types and requires proper assessment to determine appropriateness